Comparison
BPC-157 vs Methylene Blue
Side-by-side of BPC-157 and Methylene Blue. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Side-by-side
| Attribute | BPC-157 | Methylene Blue |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | Methylthioninium chloride, Provayblue, tetramethylthionine chloride |
| Half-life (hr) ↗ | 4 | 5.5 |
| Typical dose (mg) ↗ | 0.25 | 70 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia |
| Routes | subcutaneous, intramuscular, oral | oral, intravenous |
| Onset (hr) | - | 1 |
| Peak (hr) | - | 1.5 |
| Molecular weight | - | 319.85 |
| Molecular formula | C62H98N16O22 | C16H18ClN3S |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled in the US |
| Pregnancy | Insufficient data | Contraindicated |
| CAS | 137525-51-0 | 61-73-4 |
| PubChem CID | 9941957 | 6099 |
| Wikidata | Q4835418 | Q409021 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Which Should You Take?
Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is focus or working memory, pick Methylene Blue.
- → If your priority is mitochondrial function, pick Methylene Blue.
Edge case: Methylene Blue is contraindicated in pregnancy; BPC-157 is the safer pick if that applies.
Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Methylene Blue?
BPC-157 and Methylene Blue differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Methylene Blue?
BPC-157 half-life is 4 hours; Methylene Blue half-life is 5.5 hours.
Can you stack BPC-157 with Methylene Blue?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper